5 minute read
Aug. 26, 2022

SAGE-718: an Oral N-methyl-d-Aspartate Receptor (NMDAR) Positive Allosteric Modulator


oral NMDAR positive allosteric modulator Ph. II candidate in neurology from previously disclosed PAM and opt J. Med. Chem., July 2, 2022 Sage Therapeutics, Inc., Cambridge, MA

Drug Hunter Team

Context. SAGE-718 (Sage Therapeutics) is an oral N -methyl-d-aspartate receptor (NMDAR) Positive Allosteric Modulator (PAM) being developed for cognitive impairment in Huntington’s disease. Aberrant NMDAR signaling has been implicated in several neurological and psychiatric disorders, making the receptor an attractive drug target. Although [...]



Other molecules you may be interested in